Previous 10 | Next 10 |
SHANGHAI, China and SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief Executive Officer, will be pre...
SHANGHAI, China and SAN FRANCISCO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Applica...
Phase 1b Study of Niraparib in Combination with MGD013 in Advanced or Metastatic Gastric Cancer in China Registrational Bridging Study in China of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer SHANGHAI, China and SAN FRANCISCO, Feb. 04, 2020 (GLOBE NEWS...
SHANGHAI, China, and SAN FRANCISCO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the closing of its previously-announce...
Deals and Financings Celltrion (KRX: 068270), a South Korea biopharma, plans to build a $513 million China biologics manufacturing facility in Wuhan. The company said the plant's 120,000 liter capacity will make it the largest facility in China. Last summer, Celltrion announced it would fo...
Zai Lab (NASDAQ: ZLAB ) has priced its public offering of 5.5M American Depositary Shares (“ADSs”) at $47.50 per ADS, for expected gross proceeds of ~$261.3M. More news on: Zai Lab Limited, Healthcare stocks news, Read more ...
Zai Lab (NASDAQ: ZLAB ) commences a public offering of 5.5M American Depositary Shares (ADSs), each representing one ordinary share. More news on: Zai Lab Limited, Healthcare stocks news, Stocks on the move, , Read more ...
Written by Danny Cohen and Scott Matusow We have identified Five Prime Therapeutics ( FPRX ) as a potential turn-around story with upcoming pivotal data, an activist biotech fund with nearly 22% ownership, and important business decisions this year than can make this company a very l...
SHANGHAI, China and SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of Lonnie Moulder to its Board of Directors. "We are delighted to welcome Lon...
Deals and Financings Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics (GLYC) novel E-selectin-based immunotherapies in China for leukemia. Apollomics, which was incubated by OrbiMed Asia, will be responsible for developing uproleselan and GMI-1687 in...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...